Advertisement


Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study

2017 ASCO Annual Meeting

Advertisement

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)



Related Videos

Rakesh Chopra, MD, on Global Health Care: Expert Perspective

Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Breast Cancer

Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial

Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)

Bladder Cancer

Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)

Hematologic Malignancies

David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)

Advertisement

Advertisement




Advertisement